Skip to content

Emerald creates brands that support diverse customer needs. From our established medical product portfolio to our ever-expanding recreational brands, Emerald is focused on developing excellent products that you can trust.

Our new SYNCTM oils and Nano Fast-Action oral sprays are formulated with top-quality whole flower cannabis extracts grown in British Columbia. With wellness in mind, our line of smoke-free products contain all-natural ingredients and are designed to support uplifting and relaxing activities.

Emerald is passionate about growing healthy and flavourful whole-flower cannabis. Our team of expert agronomists at our state-of-the-art craft facility in Metro Vancouver are focused on producing cultivars with optimal terpene profiles in a range of THC and CBD potencies. Emerald’s whole-flower cannabis is sold across Canada in various formats; look for our products in your favourite licensed retail shops and provincial cannabis stores.

Emerald has dedicated over six years to creating controlled, precise and predictable products to help people with everyday medical conditions live better lives.

Learn more about Emerald’s established medical products and start shopping for your prescription today. 

Our SouvenirTM cannabis brand is exclusively available to the adult recreational cannabis market in Québec through SQDC online and retail stores. Souvenir is produced in Québec and is focused on bringing unique offerings to the Québec market at a competitive price point. Every batch of dried flower is hang-dried and cured to optimize terpene profiles and, once hand-packaged, promptly distributed within weeks to maintain freshness.


Rebecca Wong

Vice President, Quality and Regulatory Affairs

Ms. Wong has more than 25 years of managerial experience in quality assurance and quality control spanning research, preclinical, clinical, and commercial phases for pharmaceuticals, combination products, biologicals and medical devices. Before joining Emerald, she was the Executive Director of Quality Assurance at Novelion Therapeutics (formerly QLT Inc.), where she was the head of quality assurance, validation, compliance auditing, document management, and GxP training departments. Ms. Wong previously worked for life science companies including MDS Nordion, Cangene Corporation, and Biomira Inc. Specializing in microbiology, she earned a BSc from the University of Alberta.

Jenn Hepburn

Chief Financial Officer

Ms. Hepburn has over a decade of experience in accounting and finance and is an experienced manager of privately and publicly traded manufacturing and mining businesses operating in Canada and the USA. Prior to joining Emerald, Ms. Hepburn was the Director of Finance and Administration at bioLytical Laboratories Inc., a medical diagnostics manufacturer. Before that, she held controller positions at junior gold and silver mining companies Northern Vertex Mining Corp., Kootenay Silver Inc. and Theia Resources Ltd. Ms. Hepburn earned a BBA from Simon Fraser University and her certification from the Certified Management Accountants of British Columbia.


President & Chief Executive Officer

Mr. Bandali’s expertise in global operations, strategy development, driving innovation, M&A, and investment management has been developed over a 25-year career in the life sciences sector spanning contract clinical and research services, analytical instrumentation, lab services and venture capital.

He holds an Advanced Management Program Degree from Harvard Business School, a Master of Business Administration from McGill University, and a Bachelor of Science from the University of British Columbia. He is an innovative business leader who has built strategic and operating plans that have resulted in rapid growth and significant profitability enhancement. He has managed businesses and operations with a global footprint and has led teams of over 900 people.

Mr. Bandali’s previous experience includes serving as President, Early Phase Clinical Services and Translational Science, Syneos Health; President, Early Stage Development, as well as Chief Innovation Officer, inVentiv Health Clinical; Senior Vice President, Strategy and Business Development, AB Sciex and Molecular Devices (part of Danaher Corporation); Senior Vice President, Strategy, Legal and Corporate Development, MDS Analytical Technologies; and Vice President and General Manager, Global Early Stage Development, MDS Pharma Services. He was also Venture Partner and Vice President at MDS Capital and has served on the boards of private and public companies.